famotidine has been researched along with Purpura, Thrombotic Thrombocytopenic in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Purpura, Thrombotic Thrombocytopenic: An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kallal, SM | 1 |
| Lee, M | 1 |
1 review available for famotidine and Purpura, Thrombotic Thrombocytopenic
| Article | Year |
|---|---|
Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy.
Topics: Adrenal Cortex Hormones; Blood Transfusion; Combined Modality Therapy; Famotidine; Gastroesophageal | 1996 |